CKAP5 and Miyoshi myopathy: Collectively, our results demonstrate the broad potential of our αCD38‐tLNPs for treatment of MM for disseminated and BM‐associated cells in vivo and the ability of αCD38‐tLNPs‐siRNA‐CKAP5 to decrease disease burden in MM‐bearing mice.